

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 10/783,635  
Filed: February 20, 2004  
Page 5

**REMARKS**

Claims 49, 58-62, 64-67, 69-73 and 76-78 are pending in the subject application. Applicants have hereinabove amended claim 49 and cancelled claims 64 and 76 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in the future. Support for amended claim 49 may be found, *inter alia*, in the specification at page 10, lines 6-13, lines 25 and 26 and lines 34 and 35; page 11, lines 18-26; and page 20, lines 5-21. Applicants maintain that no issue of new matter is raised by this amendment. Upon entry of this Amendment, claim 49 as amended, and claims 58-62, 65-67, 69-73, 77 and 78 will be pending and under examination.

**Rejections under 35 U.S.C. §112, First Paragraph**

The Examiner rejected claims 49, 58-62, 64-67, 69-73 and 76-78 under 35 U.S.C. §112, first paragraph, as allegedly not enabled. Specifically, the Examiner stated the specification is enabling for methods of inhibiting the interaction between AGE and RAGE in kidney failure, for example, with quinine or quinidine, thus treating said disease states. The Examiner alleged, however, that the specification does not reasonably provide enablement for inhibiting the interaction between AGE and RAGE thus treating systemic lupus erythematosus or inflammatory lupus nephritis.

In response, applicants respectfully traverse the Examiner's ground of rejection. Nevertheless, without conceding the correctness of the Examiner's rejection, applicants note that claims 64 and 76 have been cancelled thus rendering moot the Examiner's rejection with

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 10/783,635  
Filed: February 20, 2004  
Page 6

respect to claims 64 and 76.

Applicants note further that claim 49 has been amended hereinabove. Specifically, applicants note that claim 49, as amended, does not recite a method for treating a subject suffering from systemic lupus erythematosus or inflammatory lupus nephritis. Accordingly, applicants maintain that the Examiner's rejection has been obviated.

In view of these remarks, applicants maintain that as amended, claims 49, and the claims which depend therefrom, satisfy the requirements of 35 U.S.C. §112, first paragraph. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw this ground of rejection.

#### Summary


In view of the remarks hereinabove, applicants respectfully submit that the ground of rejection set forth in the November 19, 2007 Final Office Action has been overcome. Applicants therefore respectfully request that the Examiner reconsider and withdraw the ground of rejection and allow claim 49 as amended, and claims 58-62, 65-67, 69-73, 77 and 78.

No fee, other than the \$120.00 fee for a one-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 10/783,635  
Filed: February 20, 2004  
Page 7

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

 3/19/08  
John P. White Date  
Reg. No. 28,678